

Supplementary Table 2: Mutational and clinical characteristics for patients treated or untreated with

Variables	Patients treated with ICB N=545	Patients untreated with ICB N=2 466
FGF2 status		
Amplification	32 (6%)	864 (35%)
No amplification	513 (94%)	1 602 (65%)
FGF/FGFR status		
FGF ^{Amp} /FGFR ^{Amp}	115 (21%)	1 487 (60%)
FGF ^{Amp} /FGFR ^{No Amp}	86 (16%)	459 (19%)
FGF ^{No Amp} /FGFR ^{Amp}	36 (6.6%)	53 (2%)
FGF ^{No Amp} /FGFR ^{No Amp}	308 (57%)	467 (19%)
Cancer type		
Adrenal	1 (0.2%)	-
Anal	2 (0.4%)	-
Bile duct	2 (0.4%)	-
Bladder	8 (1.5%)	-
Brain	1 (0.2%)	-
Breast	15 (2.8%)	1 065 (43%)
Choroid	2 (0.4%)	-
Colorectal	20 (3.7%)	451 (18%)
Kidney	4 (0.7%)	-
Lung	67 (12%)	498 (20%)
Melanoma	364 (67%)	452 (18%)
Esophagus	8 (1.5%)	-
ENT	10 (1.8%)	-
Ovary	7 (1.3%)	-
Pancreas	8 (1.5%)	-
Parotid	1 (0.2%)	-
Prostate	4 (0.7%)	-
Soft tissue	4 (0.7%)	-
Stomach	5 (0.9%)	-
Thyroid	1 (0.2%)	-
Urothelial	2 (0.4%)	-
Uterine	5 (0.9%)	-
Indeterminate	4 (0.7%)	-
Treatment regimen		
ICB monotherapy	456 (84%)	-
ICB in combination	88 (16%)	-
NA	1	-
Number line at ICB		
1	203 (37%)	-
2	232 (43%)	-
≥3	110 (20%)	-

ICB.

Categorical variables were described by number of observations and percentages (%).

Amp: Amplification; No Amp: No Amplification; NA: Not Available; ICB: Immune Checkpoint Blockade